Become a Patron!
True Information is the most valuable resource and we ask you to give back.
THE ONLY WEBSITE WITH THE LICENSE TO SPY!
The answer likely lies in the 10-letter “I-word” that you are not allowed to mention on social media, ivermectin.
In India Ivermectin has already been very successfull:
“The Undeniable Ivermectin Miracle in India’s 240m Populated Largest State, Uttar Pradesh – Horowitz”
All vaccines will no longer be justified as of 10/20/2021: information checked. The European Union has approved 5 therapies (https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299) that will be available in all hospitals in the Member States for the treatment of Covid. These therapies are approved by decree of the European Council (European Parliament) and will be operational from 1/10, so they will gradually be distributed around the 20/10. The vaccines were approved on a “preliminary trial basis”. However, since these 5 new drugs are required to be prescribed by decree, the use of the vaccine will be discontinued. Hence we understand why all states said “between September it is necessary that …”. You already knew everything. You have to be patient. Don’t accept blackmail. Be patient. Now that ivermectin is approved again, there is no need for a vaccine. Great news. The Pasteur Institute recognizes the effectiveness of ivermectin. A single ingestion could wipe out all of the SARS covid-19 genetic material in some people.
Good news: Ivermectin has now been scientifically recognized by researchers at the Pasteur Institute in France as an effective drug, in the prophylaxis and for the treatment of Covid-19. The results of their studies were published in the journal EMBO Molecular Medicine on July 12, 2021. An analysis of the results of other research published in the American Journal of Therapeutics urges the overriding health authority guidelines and including ivermectin as the standard of care. Macron’s government knew about it …
The Press Release states: “The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients.
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.”
The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are:
A new COVID-19 indication for existing medicines:
- baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment
Newly developed monoclonal antibodies under rolling review – a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:
- combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
- combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
- regdanvimab from Celltrion: under rolling review
- sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review
The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants. The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria.
The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes.
The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year.
The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible.
The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use.
The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe’s health systems.
The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.”